Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR | P43119 | 16/20 | 0.52 |
| ▸ | PTGDR | Q13258 | 6/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.46 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.46 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.46 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | CES1 | P23141 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4117987 | 0.93 | PTGIR (0.47) | PTGIRPTGDRMEN1KMT2AALDH1A1 | |
| SCHEMBL6958282 | 0.92 | PTGIR (0.46) | PTGIRPTGDRMEN1KMT2AALDH1A1 | |
| SCHEMBL7649622 | 0.81 | PTGIR (0.54) | PTGIRPTGDRPTGER4PTGER3PTGER2 | |
| SCHEMBL864716 | 0.80 | MAPT (0.61) | MEN1KMT2AALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL5635981 | 0.79 | TDP1 (0.47) | MEN1KMT2AALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL5088680 | 0.78 | MEN1 (0.41) | MEN1KMT2AALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL28163499 | 0.76 | CARM1 (0.49) | PTGIRPTGDRMEN1KMT2AALDH1A1 | |
| SCHEMBL11617258 | 0.76 | TDP1 (0.55) | MEN1KMT2AALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL3136962 | 0.75 | TDP1 (0.54) | MEN1KMT2AALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL2632406 | 0.75 | MAPT (0.55) | MEN1KMT2AALDH1A1TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030149107-A1 | Compounds for the treatment of metabolic disorders | PHARMA CINQ, LLC | 2003-08-07 | — | — | US | disclosed |
| US-6479520-B1 | REGULATING APOPTOSIS IN HUMAN CELLS WITH COMPOUNDS SUCH AS: 3-CYANO-6-(2-METHOXY-4-METHYLTHIOIPHENYL)-2(1H)-PYRIDINONE | CELL PATHWAYS, INC. | 2002-11-12 | — | — | US | disclosed |
| US-6046216-A | USEFUL TO INHIBIT THE GROWTH OF NEOPLASTIC CELLS. | CELL PATHWAYS, INC. (US) | 2000-04-04 | — | — | US | disclosed |
| EP-0347027-B1 | Phenylpyridone derivatives,processes for their preparation and pharmaceutical compositions containing them. | SMITH KLINE FRENCH LAB (GB) | 1994-08-03 | — | — | EP | disclosed |
| US-5254571-A | Bronchodilators, antiallergens | SMITH KLINE & FRENCH LABORATORIES LTD. (GB) | 1993-10-19 | — | — | US | disclosed |
| EP-0347027-A2 | Phenylpyridone derivatives,processes for their preparation and pharmaceutical compositions containing them. | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1989-12-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149107-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | PTGIR 535/4885PTGDR 767/4885MEN1 2137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.